2B30 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Xeris Biopharma Holdings Inc

Watchlist Manager

Watchlist

Price: 7.454 EUR 4.72% Market Closed

Market Cap: €1.1B

	Xeris Biopharma Holdings Inc F:2B30	US
B	Bombardier Inc F:BBDB	CA
F	Fluor Corp XMUN:FLU	US
F	flatexDEGIRO AG XMUN:FTK	DE
	dentalcorp Holdings Ltd TSX:DNTL	CA
	Jardine Cycle & Carriage Ltd F:CYC	SG
B	Bombardier Inc XHAM:BBDB	CA
C	Conocophillips XMUN:YCP	US

Profitability Summary

Xeris Biopharma Holdings Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

85%

Strong 3Y Average Gross Margin

83%

Gross Margin is Increasing

82% > 85%

Low Operating Margin

Negative 3Y Average Operating Margin

-18%

Operating Margin is Increasing

-47% > 9%

Low Net Margin

Negative 3Y Average Net Margin

-27%

Net Margin is Increasing

-53% > 0%

Healthy Free Cash Flow Margin

10%

Negative 3Y Average Free Cash Flow Margin

-20%

Free Cash Flow Margin is Increasing

-57% > 10%

Negative ROE

-7%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-12%

ROIC is Increasing

-28% > 10%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.